TYRA - tyra.bio Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Tyra Biosciences, Inc. (TYRA)

The P/E to earnings growth ratio reflects market expectations for Tyra Biosciences, Inc. (TYRA). This price action is driven by a lack of revenue and the cost-intensive development cycle, with the 0.00 metric serving as the target level. Growth is supported by a staff of leading oncologists operating in an agile environment, while operational stability is maintained through the full outsourcing of clinical trials to third-party contractors.

TYRA: tyra.bio Price/Earnings to Growth Multiple 07/04/2022 - 11/15/2026

Metric breakdowns and analytics for Tyra Biosciences (TYRA)

- market value and analyst target forecast:
Price Rate Chart Tyra Biosciences, Inc.|TYRA - Consensus Target
- market capitalization statistics:
Market Value Tyra Biosciences, Inc.|TYRA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Tyra Biosciences|TYRA - Company Net Assets|Market Cap to Book Value Multiple tyra.bio|TYRA - Company Total Assets
- business debt structure and liquidity details:
Total Debt to Capital Tyra Biosciences, Inc.|TYRA - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Tyra Biosciences|TYRA - Company Aggregate Debts|Debt to Net Assets Tyra Corp|TYRA - Company Long-Term Debts|Short-Term Debt Tyra Biosciences|Intermediate Liquidity Ratio tyra.bio
- earnings and valuation multiples information:
TYRA - Net Profit|Expected Net Profit Tyra Biosciences, Inc.|TYRA - P/E Multiple|Price to Future Earnings Ratio Tyra Biosciences|TYRA - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Tyra Biosciences, Inc.|TYRA - Operating profit before deduction of amortization|Earnings per share for the last four quarters Tyra Biosciences|TYRA - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months tyra.bio|TYRA - Earnings growth in current year|Expected net earnings per share growth next year Tyra Biosciences, Inc.
- sales revenue and business income indicators:
TYRA - Company Revenue|Company Future Revenue Tyra Bio|TYRA - P/S Multiple|Forward P/S Multiple Tyra Biosciences|TYRA - Sales Growth YoY (Last Twelve Months)
General company analysis:Tyra Biosciences, Inc.
Signature product of tyra.bio

The efficiency of the Tyra Biosciences, Inc. (TYRA) molecular design platform in developing oncology drugs is reflected in the PEG ratio, which currently stands at 0.00. This metric correlates the P/E multiple with earnings growth rates, making it possible to determine whether the asset's valuation is justified relative to its expansion or if the risk of overvaluation outweighs the potential for R&D success.

Competing companies

Genmab A/S (GMAB) - Price to Net Income Growth Ratio|Exelixis Inc - Price/Earnings to Growth Multiple|Nuvalent (NUVL) - Price to Earnings Adjusted for Growth Rate|KYMR: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio IDYA (IDEAYA Bio)|ELVN (Enliven Therapeutics, Inc.) - Price/Earnings to Growth Multiple|ORIC: Company Value to Earnings Growth Ratio|RLAY (Relay Corp) - PEG Multiple|PEG Multiple nurixtx.com|Price/Earnings to Growth Ratio Verastem (VSTM)|GLUE (Monte Rosa Therapeutics, Inc.) - Growth-Adjusted Payback Ratio|PEG Multiple CGEM (Cullinan Oncology)|Price to Net Income Growth Ratio Immuneering Inc.|C4 Therapeutics Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Black Diamond Therapeutics|RPTX (Repare Therapeutics) - Price/Earnings to Growth Multiple|PMVP: Company Value to Earnings Growth Ratio|KPTI (Karyopharm Therapeutics, Inc.) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Propanc Biopharma Inc PPCB|PEG Multiple BGMS|Aadi Bio - Growth-Adjusted P/E Ratio|Aileron Therapeutics - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio BPMC|GLYC: Price/Earnings to Growth Multiple|SpringWorks - Company Value to Earnings Growth Ratio